Does mitral regurgitation reduce the risks of thrombosis in atrial fibrillation and flutter?


Journal

Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752

Informations de publication

Date de publication:
Oct 2019
Historique:
pubmed: 31 7 2019
medline: 6 2 2020
entrez: 31 7 2019
Statut: ppublish

Résumé

Blood stasis is the main cause of left atrial thrombosis (LAT) in atrial tachyarrhythmias. The high-velocity flow inside the left atrium, due to mitral valve regurgitation, may prevent clot formation but the topic has never been investigated in large-scale studies. The aim of our study was to evaluate whether the presence and degree of mitral regurgitation have a protective role against LAT risk. A total of 1302 consecutive adult patients with paroxysmal or persistent atrial fibrillation or flutter undergoing cardioversion, submitted to transesophageal echocardiography, were retrospectively enrolled in the study. The study population was divided into three groups according to the mitral regurgitation degree: absent, mild-to-moderate and severe. Among 1302 patients enrolled in the study, patients without mitral regurgitation were 248 (19%), those with mild-to-moderate 970 (75%), whereas 84 had severe mitral regurgitation (6%). LAT incidence was significantly lower in patients with severe mitral regurgitation compared with those with mild-to-moderate (mitral regurgitation) (2.4 vs. 8.9%, P < 0.05), and similar to subjects without mitral regurgitation (2.4%). Despite patients with severe regurgitation having clinical and echo characteristics predisposing to LAT (higher age, heart failure, higher atrial size, lower ventricular function) thrombosis prevalence was significantly lower than for those with mild-to-moderate mitral regurgitation. The percentage of LAT in severe mitral regurgitation cases was very low and similar to that of cases without regurgitation which were characterized by lower age, normal left ventricular function or other risk factors, reinforcing the hypothesis of a protecting role against atrial thrombosis of mitral regurgitation.

Identifiants

pubmed: 31361652
doi: 10.2459/JCM.0000000000000838
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

660-666

Auteurs

Alberto Cresti (A)

Cardioneurovascular Department, Grosseto Hospital, Azienda USL Toscana Sudest.

Claudia A Galli (CA)

Centro Cardiologico Monzino IRCCS, Milano, Milano, Italy.

Marina L Alimento (ML)

Centro Cardiologico Monzino IRCCS, Milano, Milano, Italy.

Francesco De Sensi (F)

Cardioneurovascular Department, Grosseto Hospital, Azienda USL Toscana Sudest.

Pasquale Baratta (P)

Cardioneurovascular Department, Grosseto Hospital, Azienda USL Toscana Sudest.

Incoronata D'Aiello (I)

Cardioneurovascular Department, Grosseto Hospital, Azienda USL Toscana Sudest.

Ugo Limbruno (U)

Cardioneurovascular Department, Grosseto Hospital, Azienda USL Toscana Sudest.

Mauro Pepi (M)

Centro Cardiologico Monzino IRCCS, Milano, Milano, Italy.

Laura Fusini (L)

Cardioneurovascular Department, Grosseto Hospital, Azienda USL Toscana Sudest.

Anna C Maltagliati (AC)

Centro Cardiologico Monzino IRCCS, Milano, Milano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH